Loading…
Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents
Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the w...
Saved in:
Published in: | Antibiotics (Basel) 2022-10, Vol.11 (10), p.1431 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163 |
---|---|
cites | cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163 |
container_end_page | |
container_issue | 10 |
container_start_page | 1431 |
container_title | Antibiotics (Basel) |
container_volume | 11 |
creator | Arrigoni, Roberto Ballini, Andrea Topi, Skender Bottalico, Lucrezia Jirillo, Emilio Santacroce, Luigi |
description | Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics. |
doi_str_mv | 10.3390/antibiotics11101431 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372</doaj_id><sourcerecordid>2728412444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</originalsourceid><addsrcrecordid>eNptkt1qFTEQxxdRsNQ-QW8C3nizmq_dJDfCsdhaqFqkvQ7ZfBxzyNnUJFvoY_SNndNTSivmJjOZ__xmMkzXHRP8kTGFP5m5xSnmFm0lhGDCGXnVHVAsVD8ySV8_s992R7VuMBxFmMTyoLtfPWWjX77G2sxsPWoZfb-zeTK2-RKXLWrL5ItdUgYJMrNDl7l5SDUJXVePckA_TFsKuLvgl5hTXkcL7mXJbrENkipaJaDNpsVbj3Z1-2c1QLpaA7G-694Ek6o_erwPu-vTr1cn3_qLn2fnJ6uL3nI8tp4KMXBmxEC59M4yPropCEVFENNEBjmMEoPJJxN8cJg4IQhlWFJnOcVkZIfd-Z7rstnomxK3ptzpbKJ-eMhlrU2BsSSvhecjdWG0gQxcKGIctjwITyaMCRMUWJ_3rJtl2kI38A8YxQvoy8gcf-t1vtVqUJJyAYAPj4CS_yy-Nr2N1fqUzOzzUjUVVA1EcKlA-v4f6SYvMNX0oJKcUM45qNheZUuutfjw1AzBerc2-j9rw_4C8C27nA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728412444</pqid></control><display><type>article</type><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</creator><creatorcontrib>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</creatorcontrib><description>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</description><identifier>ISSN: 2079-6382</identifier><identifier>EISSN: 2079-6382</identifier><identifier>DOI: 10.3390/antibiotics11101431</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antibacterial activity ; Antibiotic resistance ; Antibiotics ; Antimicrobial agents ; Antimicrobial peptides ; Bacteria ; Biofilms ; Biological products ; Cell walls ; Cytokines ; DNA methylation ; Drug resistance ; Efflux ; Growth factors ; HIV ; Human immunodeficiency virus ; Immune response ; Immune system ; immunity ; Immunoregulation ; Infections ; Infectious diseases ; Inflammation ; Interferon ; Interleukin 10 ; Isoniazid ; Lymphocytes T ; Macrophages ; Microbiota ; multi-drug resistant Mycobacterium tuberculosis strains ; Multidrug resistance ; Mycobacterium tuberculosis ; Natural products ; Peptides ; Polyphenols ; Probiotics ; Pyrazinamide ; Review ; Rifampin ; Strains (organisms) ; Stringent response ; Tuberculosis ; Tumor necrosis factor-TNF ; γ-Interferon</subject><ispartof>Antibiotics (Basel), 2022-10, Vol.11 (10), p.1431</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</citedby><cites>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</cites><orcidid>0000-0001-5671-8124 ; 0000-0001-8758-1415 ; 0000-0003-4176-3939 ; 0000-0001-5361-4346</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2728412444/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2728412444?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids></links><search><creatorcontrib>Arrigoni, Roberto</creatorcontrib><creatorcontrib>Ballini, Andrea</creatorcontrib><creatorcontrib>Topi, Skender</creatorcontrib><creatorcontrib>Bottalico, Lucrezia</creatorcontrib><creatorcontrib>Jirillo, Emilio</creatorcontrib><creatorcontrib>Santacroce, Luigi</creatorcontrib><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><title>Antibiotics (Basel)</title><description>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</description><subject>Antibacterial activity</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial peptides</subject><subject>Bacteria</subject><subject>Biofilms</subject><subject>Biological products</subject><subject>Cell walls</subject><subject>Cytokines</subject><subject>DNA methylation</subject><subject>Drug resistance</subject><subject>Efflux</subject><subject>Growth factors</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune response</subject><subject>Immune system</subject><subject>immunity</subject><subject>Immunoregulation</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Interleukin 10</subject><subject>Isoniazid</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Microbiota</subject><subject>multi-drug resistant Mycobacterium tuberculosis strains</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis</subject><subject>Natural products</subject><subject>Peptides</subject><subject>Polyphenols</subject><subject>Probiotics</subject><subject>Pyrazinamide</subject><subject>Review</subject><subject>Rifampin</subject><subject>Strains (organisms)</subject><subject>Stringent response</subject><subject>Tuberculosis</subject><subject>Tumor necrosis factor-TNF</subject><subject>γ-Interferon</subject><issn>2079-6382</issn><issn>2079-6382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt1qFTEQxxdRsNQ-QW8C3nizmq_dJDfCsdhaqFqkvQ7ZfBxzyNnUJFvoY_SNndNTSivmJjOZ__xmMkzXHRP8kTGFP5m5xSnmFm0lhGDCGXnVHVAsVD8ySV8_s992R7VuMBxFmMTyoLtfPWWjX77G2sxsPWoZfb-zeTK2-RKXLWrL5ItdUgYJMrNDl7l5SDUJXVePckA_TFsKuLvgl5hTXkcL7mXJbrENkipaJaDNpsVbj3Z1-2c1QLpaA7G-694Ek6o_erwPu-vTr1cn3_qLn2fnJ6uL3nI8tp4KMXBmxEC59M4yPropCEVFENNEBjmMEoPJJxN8cJg4IQhlWFJnOcVkZIfd-Z7rstnomxK3ptzpbKJ-eMhlrU2BsSSvhecjdWG0gQxcKGIctjwITyaMCRMUWJ_3rJtl2kI38A8YxQvoy8gcf-t1vtVqUJJyAYAPj4CS_yy-Nr2N1fqUzOzzUjUVVA1EcKlA-v4f6SYvMNX0oJKcUM45qNheZUuutfjw1AzBerc2-j9rw_4C8C27nA</recordid><startdate>20221018</startdate><enddate>20221018</enddate><creator>Arrigoni, Roberto</creator><creator>Ballini, Andrea</creator><creator>Topi, Skender</creator><creator>Bottalico, Lucrezia</creator><creator>Jirillo, Emilio</creator><creator>Santacroce, Luigi</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5671-8124</orcidid><orcidid>https://orcid.org/0000-0001-8758-1415</orcidid><orcidid>https://orcid.org/0000-0003-4176-3939</orcidid><orcidid>https://orcid.org/0000-0001-5361-4346</orcidid></search><sort><creationdate>20221018</creationdate><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><author>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibacterial activity</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial peptides</topic><topic>Bacteria</topic><topic>Biofilms</topic><topic>Biological products</topic><topic>Cell walls</topic><topic>Cytokines</topic><topic>DNA methylation</topic><topic>Drug resistance</topic><topic>Efflux</topic><topic>Growth factors</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune response</topic><topic>Immune system</topic><topic>immunity</topic><topic>Immunoregulation</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Interleukin 10</topic><topic>Isoniazid</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Microbiota</topic><topic>multi-drug resistant Mycobacterium tuberculosis strains</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis</topic><topic>Natural products</topic><topic>Peptides</topic><topic>Polyphenols</topic><topic>Probiotics</topic><topic>Pyrazinamide</topic><topic>Review</topic><topic>Rifampin</topic><topic>Strains (organisms)</topic><topic>Stringent response</topic><topic>Tuberculosis</topic><topic>Tumor necrosis factor-TNF</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arrigoni, Roberto</creatorcontrib><creatorcontrib>Ballini, Andrea</creatorcontrib><creatorcontrib>Topi, Skender</creatorcontrib><creatorcontrib>Bottalico, Lucrezia</creatorcontrib><creatorcontrib>Jirillo, Emilio</creatorcontrib><creatorcontrib>Santacroce, Luigi</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Antibiotics (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arrigoni, Roberto</au><au>Ballini, Andrea</au><au>Topi, Skender</au><au>Bottalico, Lucrezia</au><au>Jirillo, Emilio</au><au>Santacroce, Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</atitle><jtitle>Antibiotics (Basel)</jtitle><date>2022-10-18</date><risdate>2022</risdate><volume>11</volume><issue>10</issue><spage>1431</spage><pages>1431-</pages><issn>2079-6382</issn><eissn>2079-6382</eissn><abstract>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/antibiotics11101431</doi><orcidid>https://orcid.org/0000-0001-5671-8124</orcidid><orcidid>https://orcid.org/0000-0001-8758-1415</orcidid><orcidid>https://orcid.org/0000-0003-4176-3939</orcidid><orcidid>https://orcid.org/0000-0001-5361-4346</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2079-6382 |
ispartof | Antibiotics (Basel), 2022-10, Vol.11 (10), p.1431 |
issn | 2079-6382 2079-6382 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372 |
source | Publicly Available Content Database; PubMed Central |
subjects | Antibacterial activity Antibiotic resistance Antibiotics Antimicrobial agents Antimicrobial peptides Bacteria Biofilms Biological products Cell walls Cytokines DNA methylation Drug resistance Efflux Growth factors HIV Human immunodeficiency virus Immune response Immune system immunity Immunoregulation Infections Infectious diseases Inflammation Interferon Interleukin 10 Isoniazid Lymphocytes T Macrophages Microbiota multi-drug resistant Mycobacterium tuberculosis strains Multidrug resistance Mycobacterium tuberculosis Natural products Peptides Polyphenols Probiotics Pyrazinamide Review Rifampin Strains (organisms) Stringent response Tuberculosis Tumor necrosis factor-TNF γ-Interferon |
title | Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A57%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Resistance%20to%20Mycobacterium%20tuberculosis%20and%20Potential%20Use%20of%20Natural%20and%20Biological%20Products%20as%20Alternative%20Anti-Mycobacterial%20Agents&rft.jtitle=Antibiotics%20(Basel)&rft.au=Arrigoni,%20Roberto&rft.date=2022-10-18&rft.volume=11&rft.issue=10&rft.spage=1431&rft.pages=1431-&rft.issn=2079-6382&rft.eissn=2079-6382&rft_id=info:doi/10.3390/antibiotics11101431&rft_dat=%3Cproquest_doaj_%3E2728412444%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728412444&rft_id=info:pmid/&rfr_iscdi=true |